THE SUPREME COURT *of* OHIO

Who Are We Serving?

Early Results from Ohio Specialized Dockets Data Collection

Standard 12

Sup.R. 36.20(A)
Standard 12. Effectiveness Evaluation

A specialized docket judge shall evaluate the effectiveness of the specialized docket by doing each of the following:

(A) Reporting data as required by the Supreme Court, including information to assess compliance with these standards;

(B) Engaging in on-going data collection in order to evaluate whether the specialized docket is meeting its goals and objectives.

Data Driven Decision Making

- Why are we doing what we are doing?

- Are we doing what we said we would do?

- Are we doing it in a quality way?

- Is it making a difference?

Multi-Purpose Data

- **Inform policy** – Learn what works and what doesn't

- **Support operations** – Monitor, evaluate, report, plan, budget

- **Educate stakeholders** – Tell our story

Standard 12 Reporting Process

- Data collection started July 1, 2019

- Data collected:

    - Referrals, referral process, and outcomes

    - Participants, participation process, outcomes

- Reports required at least once a month, but no later than the 15th of the month following the month with activity

- Validation checks and error messages

Overview of Data Elements

- Personal identifiers
- Referral
- Demographics
- Minor children
- Clinical assessment
- Risk assessment
- Substance of use

- Acceptance status
- OARRS flag
- Social functioning
- Treatment
- In-program recidivism
- Funding sources
- Participation outcome

The Ohio Landscape

Overview as of January 31, 2020

- **5,366** participants
- **225** dockets
- **63** counties (72%)
- **13** types of dockets

Participants by County

Docket Types and Sizes

Docket Type	Participants	% of Total
Drug	3,069	57.2%
Mental Health	691	12.9%
Family Dependency	446	8.3%
Veterans	370	6.9%
Reentry	240	4.5%
Human Trafficking	141	2.6%
Domestic Violence	121	2.3%
OVI	121	2.3%
SAMI	59	1.1%
Child Support	41	0.8%
Truancy	32	0.6%
Juvenile Treatment	30	0.6%
Sex Offender	5	0.1%
Total	**5,366**	

Participants	Dockets	% of Total
25 or less	155	68.9%
26 to 50	48	21.3%
51 to 75	15	6.7%
76 to 100	3	1.3%
101 to 125	3	1.3%
126 to 150	0	0.0%
151 to 175	1	0.4%
Total	**225**	

Participant Snapshots

- Substances of use

- Race and ethnicity

- Gender

- Age

- Funding sources

Primary Substance of Use

Substance	Number	Percentage	Substance	Number	Percentage
Heroin	1,557	31.5%	Oxycodone	27	0.5%
Amphetamines	855	17.3%	Buprenorphine	18	0.4%
Alcohol	770	15.6%	Methadone	12	0.2%
Cannabinoids	750	15.2%	Methaqualone	9	0.2%
Cocaine	497	10.0%	Phencyclidine	9	0.2%
Prescription Opiates	358	7.2%	Unknown	4	0.1%
Fentanyl	130	2.6%	Carfentanil	2	0.04%
Benzodiazepines	33	0.7%	**Total**	**4,950**	**100.0%**
			No Substance Use	335	6.2%

Substance	Percentage
Any Opioid	42.5%
Amphetamines or Cocaine	27.3%
Total	**69.8%**

Participant Race and Ethnicity

Race	Total	Hispanic	Non-Hispanic
Asian or Pacific Islander alone	0.4%	0.0%	0.4%
Black alone	16.0%	0.1%	16.0%
Native American alone	0.2%	0.0%	0.1%
White alone	80.6%	1.4%	79.2%
Multi	2.1%	0.1%	2.0%
Unknown	0.7%	0.5%	0.3%
Total	**100.0%**	**2.1%**	**97.9%**

Participant Gender

Gender	Number	Percentage
Female	2,387	44.5%
Male	2,969	55.3%
Non-Binary	2	0.0%
No Data	8	0.1%
Total	**5,366**	**100.0%**

Participant Age

Mean Age

33

Age Group	Number	Percentage
Under 18	256	4.8%
18 to 29	1,792	33.5%
30 to 39	1,941	36.3%
40 to 49	835	15.6%
50 to 59	386	7.2%
60 to 69	122	2.3%
70 to 79	12	0.2%
Total	**5,344**	**100.0%**

Treatment Funding

	Participants	% of Total
Medicaid Funding	3,607	70.0%
Other Funding	1,546	30.0%
Total Participants	**5,153**	

Primary Substance of Use - Race

Substance	White alone	Black alone	Multi	Asian or Pac. Isl. alone	Native American alone	Total	N
Alcohol	12.9%	21.6%	9.6%	36.8%	11.1%	14.3%	762
Amphetamines	18.6%	3.6%	10.5%	5.3%	11.1%	16.0%	851
Benzodiazepines	0.7%	0.5%	0.0%	0.0%	0.0%	0.6%	33
Buprenorphine	0.4%	0.1%	0.0%	0.0%	0.0%	0.3%	18
Cannabinoids	10.5%	29.3%	29.8%	15.8%	22.2%	14.0%	744
Carfentanil	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	2
Cocaine	7.1%	20.3%	9.6%	5.3%	0.0%	9.2%	492
Fentanyl	2.7%	1.3%	2.6%	0.0%	0.0%	2.4%	130
Heroin	33.9%	6.2%	17.5%	26.3%	55.6%	29.0%	1,547
Methadone	0.3%	0.0%	0.0%	0.0%	0.0%	0.2%	12
Methaqualone	0.2%	0.0%	0.9%	0.0%	0.0%	0.2%	9
Oxycodone	0.6%	0.2%	0.0%	0.0%	0.0%	0.5%	27
Phencyclidine	0.0%	0.8%	0.0%	0.0%	0.0%	0.2%	9
Prescription Opiates	7.2%	3.9%	8.8%	5.3%	0.0%	6.7%	356
Unknown	0.0%	0.1%	0.9%	0.0%	0.0%	0.1%	4
Total	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	5,327
N	4,324	861	114	19	9	5,327	

Primary Substance of Use - Gender

Substance	Female	Male	N
Alcohol	27.7%	72.2%	765
Amphetamines	51.9%	48.1%	853
Benzodiazepines	45.5%	54.5%	33
Buprenorphine	38.9%	61.1%	18
Cannabinoids	28.4%	71.6%	750
Carfentanil	0.0%	100.0%	2
Cocaine	49.0%	51.0%	496
Fentanyl	53.1%	46.9%	130
Heroin	54.8%	45.2%	1,557
Methadone	33.3%	66.7%	12
Methaqualone	55.6%	44.4%	9
Oxycodone	59.3%	40.7%	27
Phencyclidine	22.2%	77.8%	9
Prescription Opiates	54.5%	45.5%	358
Unknown	25.0%	75.0%	4
Total	**44.6%**	**55.4%**	**5,358**

Substance	Female	Male
Any Opioid	54.4%	45.6%
Amphetamines or Cocaine	50.9%	49.1%

Primary Substance of Use - Age

Substance	Under 18	18 to 29	30 to 39	40 to 49	50 to 59	60 to 69	70 to 79	N
Alcohol	2.6%	9.1%	13.2%	20.6%	40.7%	39.8%	80.0%	768
Amphetamines	3.1%	17.4%	18.6%	20.0%	12.0%	3.5%	0.0%	851
Benzodiazepines	0.5%	0.8%	0.5%	0.9%	0.0%	1.8%	0.0%	33
Buprenorphine	0.0%	0.5%	0.5%	0.0%	0.3%	0.0%	0.0%	18
Cannabinoids	91.1%	19.7%	8.7%	6.8%	4.7%	5.3%	10.0%	745
Carfentanil	0.0%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	2
Cocaine	0.5%	7.4%	7.8%	13.9%	20.6%	35.4%	0.0%	495
Fentanyl	0.0%	2.7%	3.1%	2.6%	0.8%	0.9%	0.0%	129
Heroin	1.6%	33.2%	38.6%	27.0%	13.9%	8.8%	0.0%	1,553
Methadone	0.0%	0.3%	0.2%	0.3%	0.3%	0.0%	0.0%	12
Methaqualone	0.0%	0.4%	0.1%	0.3%	0.0%	0.0%	0.0%	9
Oxycodone	0.0%	0.9%	0.3%	0.4%	0.6%	1.8%	0.0%	27
Phencyclidine	0.0%	0.1%	0.2%	0.3%	0.3%	0.9%	0.0%	9
Prescription Opiates	0.5%	7.2%	8.4%	7.0%	5.8%	0.9%	10.0%	356
Unknown	0.0%	0.2%	0.0%	0.0%	0.0%	0.9%	0.0%	4
Total	**100.0%**	**100.0%**	**100.0%**	**100.0%**	**100.0%**	**100.0%**	**100.0%**	
N	**192**	**1,674**	**1,867**	**796**	**359**	**113**	**10**	**5,011**

Key Performance Indicators

Timeliness Measures

- Referral date to acceptance decision

- Assessment referral to assessment completion

- Referral date to treatment start date

Days from Referral to Acceptance Decision

Days	Decision / Percent of Participants		
	Accept	Opt Out	Did Not Meet Criteria
15 or less	41.0%	42.0%	53.5%
16 to 30	21.5%	19.3%	23.4%
31 to 60	21.5%	21.9%	16.1%
61 to 90	8.1%	8.6%	3.8%
91 to 120	3.1%	3.7%	1.6%
121 to 150	1.8%	2.6%	1.1%
151 to 180	0.9%	1.9%	0.4%
181 to 270	1.3%	0.0%	0.1%
271 to 365	0.7%	0.0%	0.0%
Mean Days	**34**	**33**	**22**
N	**6,758**	**269**	**740**

Days from Assessment Referral to Assessment Completion

Mean Days

16

Days	% of Participants
0 or 1	32.4%
2 to 15	40.0%
16 to 30	15.0%
31 to 60	7.7%
61 to 90	2.3%
91 to 120	1.0%
121 to 150	0.5%
151 to 180	0.2%
181 to 270	0.4%
271 to 365	0.4%

Days from Referral to Treatment Start

Mean Days

51

Days	% of Participants
15 or less	25.1%
16 to 30	21.2%
31 to 60	26.2%
61 to 90	13.1%
91 to 120	5.4%
121 to 150	3.0%
151 to 180	1.5%
181 to 270	3.0%
271 to 365	1.5%

Social Functioning

- Employment

- School/vocational training

What's Next?

- Evolution of the data collection process

- Key performance indicators

- Portal-based downloadable reports

Contact Information

Monica Kagey
Specialized Dockets Section
Supreme Court of Ohio

monica.kagey@sc.ohio.gov

614-387-9427